Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer

Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer seem to have a higher risk of osteoporosis.

This makes sense.

These drugs slow the growth of prostate cancer by suppressing testosterone production.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote